In 20,330 girls aged 12-16, one dose of bivalent or nonavalent HPV vaccine was noninferior to two doses against persistent HPV16/18 infection (rate differences -0.13 and 0.21 per 100); vaccine effectiveness was at least 97% in all groups.
Clinical trialn = 20,330
Kreimer et al. Noninferiority of One HPV Vaccine Dose to Two Doses